Home >Current Issue
Volume: 9, Issue: 2, February, 2019
A validated LC-MS/MS method for the pharmacokinetic study of alogliptin in healthy rabbitsAuthor Affiliations
A liquid chromatography-tandem mass spectrophotometric (LC-MS/MS) method was developed for quantification of Alogliptin in rabbit plasma employing Liquid-Liquid extraction technique. The developed method was validated for specificity, precision, accuracy, recovery, and stability characteristics. Chromatographic separation was achieved on Inertsil ODS 5 µm C18, 50 × 4.60 mm with 30:70 v/v of 0.1% formic acids: Organic Mixture (acetonitrile: methanol, 80:20% v/v) as an isocratic mobile phase with a flow rate of 1.0 ml/min. the developed LC-MS method was applied to assess pharmacokinetics parameters of alogliptin tablet in healthy rabbits. Alogliptin showed Tmax of 2.6 ± 0.37 h and mean Cmax, AUC 0-t and AUC0 for test formulation is 90.6 ± 4.41, 1675.41 ± 164 and 3726.47 ± 796 respectively.
Copyright: The Author(s). This is an open access article distributed under the Creative Commons Attribution Non-Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shawet JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014;103(2):137-149. https://doi.org/10.1016/j.diabres.2013.11.002
Meier JJ. Beta cell mass in diabetes: a realistic therapeutic target? Diabetologia 2008;51(5):703-713. https://doi.org/10.1007/s00125-008-0936-9
Kaneto H, Katakami N, Matsuhisa M, Taka-aki M. Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediat Inflamm 2010;2010:1-12. https://doi.org/10.1155/2010/453892
Robertson RP, Harmon J, Tran POT. B-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004; 53:119-24. https://doi.org/10.2337/diabetes.53.2007.S119
Drucker DJ. Glucagon-like peptides. Diabetes.1998;47:159-169. https://doi.org/10.2337/diab.47.2.159
Nauck MA. Is glucagon-like peptide-1 an incretin hormone? Diabetologia 1999;42(3):373-379. https://doi.org/10.1007/s001250051165
Wang Y, Egan JM, Raygada M. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology 1995;136:4910-4917. https://doi.org/10.1210/endo.136.11.7588224
Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995;136(8):3585-3596. https://doi.org/10.1210/endo.136.8.7628397
Deacon CF, Nauck MA, Toft-Nielsen M. Both subcutaneously and intravenously administered glucagonlike peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44(9):1126-1131. https://doi.org/10.2337/diab.44.9.1126
Moritoh, Y., Takeuchi, K., Asakawa, T., Kataoka, O., Odaka, H. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. Eur. J. Pharmacol. 2009;602:448–54. https://doi.org/10.1016/j.ejphar.2008.11.017
Yadav J, Kadam V, Mohite K, J. Curr. Pharma Res. 2014; 4:1286–1290.
Sharma K and Parle A. Int. Bull. Drug Res. 2015; 5: 81–89.
El-Bagary R, I Elkady E, F Ayoub BM. Int. J. Biomed. Sci. 2012; 8:215–218.
Zhang K, Ma P, Jing W, Zhang X. Asian J. Pharm. Sci. 2015;10:152–158.
Deng J, Guo J, Dai R, Zhang G, Xie H. J. Pharm. Biomed. Anal. 2015;117:99–103. https://doi.org/10.1016/j.jpba.2015.08.033
Yadav J, Jadhav S, Mohite K, Int. J. Pharm. Pharm. Res. 2014;1:1–9.
ICH guidelines for the stability of new drug substances and products. Q1A(R2) ICH, Geneva; 2005. p. 1-13.
ICH guidelines for validation of analytical procedures: text and methodology. Q2(R1) ICH, Geneva; 2005. p. 1-14.